BioArctic Management
Management criteria checks 2/4
BioArctic's CEO is Gunilla Osswald, appointed in Jan 2014, has a tenure of 10.83 years. total yearly compensation is SEK22.38M, comprised of 19.8% salary and 80.2% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth SEK16.90M. The average tenure of the management team and the board of directors is 5.8 years and 6.8 years respectively.
Key information
Gunilla Osswald
Chief executive officer
SEK 22.4m
Total compensation
| CEO salary percentage | 19.8% |
| CEO tenure | 10.8yrs |
| CEO ownership | 0.1% |
| Management average tenure | 5.8yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Sep 01
Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024
Aug 15Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)
Apr 13News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 19News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 03Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues
Dec 23With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case
Nov 12BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be
Jul 21Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results
Jul 15New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)
Jul 07Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade
May 06Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth
Mar 13Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher
Nov 30We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn
Sep 16We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow
Apr 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -SEK 233m |
| Jun 30 2024 | n/a | n/a | -SEK 88m |
| Mar 31 2024 | n/a | n/a | -SEK 122m |
| Dec 31 2023 | SEK 22m | SEK 4m | SEK 229m |
| Sep 30 2023 | n/a | n/a | SEK 259m |
| Jun 30 2023 | n/a | n/a | SEK 270m |
| Mar 31 2023 | n/a | n/a | SEK 327m |
| Dec 31 2022 | SEK 9m | SEK 5m | -SEK 11m |
| Sep 30 2022 | n/a | n/a | SEK 28m |
| Jun 30 2022 | n/a | n/a | -SEK 147m |
| Mar 31 2022 | n/a | n/a | -SEK 135m |
| Dec 31 2021 | SEK 5m | SEK 3m | -SEK 120m |
| Sep 30 2021 | n/a | n/a | -SEK 114m |
| Jun 30 2021 | n/a | n/a | -SEK 97m |
| Mar 31 2021 | n/a | n/a | -SEK 101m |
| Dec 31 2020 | SEK 5m | SEK 3m | -SEK 69m |
| Sep 30 2020 | n/a | n/a | -SEK 72m |
| Jun 30 2020 | n/a | n/a | -SEK 60m |
| Mar 31 2020 | n/a | n/a | SEK 78m |
| Dec 31 2019 | SEK 7m | SEK 3m | SEK 88m |
| Sep 30 2019 | n/a | n/a | SEK 441m |
| Jun 30 2019 | n/a | n/a | SEK 475m |
| Mar 31 2019 | n/a | n/a | SEK 380m |
| Dec 31 2018 | SEK 5m | SEK 3m | SEK 382m |
| Sep 30 2018 | n/a | n/a | SEK 58m |
| Jun 30 2018 | n/a | n/a | SEK 32m |
| Mar 31 2018 | n/a | n/a | SEK 29m |
| Dec 31 2017 | SEK 3m | SEK 2m | SEK 15m |
Compensation vs Market: Gunilla's total compensation ($USD2.04M) is above average for companies of similar size in the Swedish market ($USD906.72K).
Compensation vs Earnings: Gunilla's compensation has increased whilst the company is unprofitable.
CEO
Gunilla Osswald (63 yo)
10.8yrs
Tenure
SEK 22,378,000
Compensation
Dr. Gunilla Osswald, PhD has been the Chief Executive Officer and President of BioArctic AB (publ) since 2014. Dr. Osswald has been a Director of Egetis Therapeutics AB (publ) (formerly known as PledPharma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 10.8yrs | SEK 22.38m | 0.11% SEK 16.9m | |
| Co-Founder | 21.8yrs | SEK 390.00k | no data | |
| Co-Founder | 21.8yrs | SEK 2.54m | 33.41% SEK 5.3b | |
| Chief Financial Officer | 1.5yrs | no data | no data | |
| Chief Research Officer & Head of Research | no data | no data | 0.051% SEK 8.0m | |
| VP of Pre-Clinical Development & Chief Scientific Officer | 18.8yrs | no data | 0.063% SEK 10.0m | |
| VP and Head of IR & Communication | 4.5yrs | no data | 0.016% SEK 2.6m | |
| General Counsel and Head of Legal & IP | no data | no data | no data | |
| Head of Public Affairs | 2.6yrs | no data | no data | |
| Head of Marketing | 2.8yrs | no data | no data | |
| Vice President of Human Resources | 5.8yrs | no data | no data | |
| VP & Head of CMC | no data | no data | 0.011% SEK 1.7m |
5.8yrs
Average Tenure
63yo
Average Age
Experienced Management: BIOA B's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 21.8yrs | SEK 390.00k | no data | |
| Co-Founder | 21.8yrs | SEK 2.54m | 33.41% SEK 5.3b | |
| Independent Chairman | 7.2yrs | SEK 621.00k | 0.10% SEK 15.9m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Board | no data | no data | no data | |
| Independent Director | 1.4yrs | SEK 187.00k | no data | |
| Independent Director | 6.5yrs | SEK 316.00k | 0.032% SEK 5.1m | |
| Independent Director | 3.5yrs | SEK 318.00k | 0.0036% SEK 564.1k | |
| Member of Scientific Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
6.8yrs
Average Tenure
70yo
Average Age
Experienced Board: BIOA B's board of directors are considered experienced (6.8 years average tenure).